Pfizer Inc. (PFE)

36.15
0.21 0.58
NYSE : Health Technology
Prev Close 36.36
Open 36.13
Day Low/High 35.73 / 36.22
52 Wk Low/High 32.32 / 39.43
Volume 20.88M
Avg Volume 20.39M
Exchange NYSE
Shares Outstanding 5.85B
Market Cap 211.52B
EPS 3.60
P/E Ratio 10.04
Div & Yield 1.36 (3.64%)

Latest News

Pfizer Announces Extension Of Zithromax® Antibiotic Donation Program Through 2025 To Help Eliminate World's Leading Infectious Cause Of Blindness

Pfizer Announces Extension Of Zithromax® Antibiotic Donation Program Through 2025 To Help Eliminate World's Leading Infectious Cause Of Blindness

Pfizer Inc. announced today it will extend its donation of the antibiotic Zithromax® (azithromycin) to the International Trachoma Initiative through 2025, building on the company's 20-years of work to help eliminate the world's leading infectious cause of...

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.

Pfizer To Expand Venture Investing With $600 Million Commitment To Pfizer Ventures

Pfizer To Expand Venture Investing With $600 Million Commitment To Pfizer Ventures

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company's venture investment vehicle.

Dacomitinib Shows More Than Seven-Month Improvement In Overall Survival Compared To An Established Therapy In Advanced NSCLC With EGFR-Activating Mutations

Dacomitinib Shows More Than Seven-Month Improvement In Overall Survival Compared To An Established Therapy In Advanced NSCLC With EGFR-Activating Mutations

Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) data from the ARCHER 1050 trial evaluating dacomitinib as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating...

Exiting Allergan

After a lot of patience and disappointment, we are closing our remaining small 'spec' position.

Two-Year Update Of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses With BAVENCIO® (avelumab)

Two-Year Update Of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses With BAVENCIO® (avelumab)

CHICAGO, June 4, 2018 /PRNewswire/ -- Not intended for UK-based media   Two- year follow-up data on meaningful durable responses , overall survival (OS) and progression-free survival (PFS) to be presented in patients with metastatic Merkel cell carcinoma...

Pfizer Receives Positive CHMP Opinion For Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

Pfizer Receives Positive CHMP Opinion For Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

Pfizer Inc. (NYSE:PFE) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for TRAZIMERA™, a potential biosimilar to...

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

Pfizer's XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation In Two New Indications

Pfizer's XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation In Two New Indications

Pfizer Inc. (NYSE:PFE) announced today that the U.

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

FDA Grants Breakthrough Therapy Designation For Tafamidis For The Treatment Of Patients With Transthyretin Cardiomyopathy

FDA Grants Breakthrough Therapy Designation For Tafamidis For The Treatment Of Patients With Transthyretin Cardiomyopathy

Pfizer Inc. (NYSE:PFE) announced today that tafamidis received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients with transthyretin cardiomyopathy, a rare, fatal, and underdiagnosed condition...

A Study Analyzing Observational Data Shows Real-World Effectiveness Of Prevnar® 13 In Adults Age 65

A Study Analyzing Observational Data Shows Real-World Effectiveness Of Prevnar® 13 In Adults Age 65

Pfizer Inc. (NYSE: PFE) announced today that results from a study analyzing real-world effectiveness data found that Prevnar 13 ® (pneumococcal 13-valent conjugate vaccine [diphtheria CRM 197 Protein]) reduced the risk of hospitalization from vaccine-type...

Pfizer Begins A Phase 1/2 Study To Evaluate Respiratory Syncytial Virus (RSV) Vaccine

Pfizer Begins A Phase 1/2 Study To Evaluate Respiratory Syncytial Virus (RSV) Vaccine

Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers.

FDA Publicly Shames Drug Companies to Encourage Generic Competition

FDA Publicly Shames Drug Companies to Encourage Generic Competition

Following up on President Trump's drug pricing speech last week, the FDA posted a list of 39 name-brand drug firms that are allegedly making life tough on generic drug companies.

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 5/18/18)

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Friday 5/18/18)

Why study charts? Because they're like footprints at the scene of the crime, clues to what the big money managers are likely thinking, Jim Cramer says.

Invacare Corporation Appoints Petra Danielsohn-Weil, PhD, To Board Of Directors

Invacare Corporation Appoints Petra Danielsohn-Weil, PhD, To Board Of Directors

Invacare Corporation (NYSE: IVC) today announced the appointment of Petra Danielsohn-Weil, PhD, to its Board of Directors, effective May 17, 2018.

LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial In Pediatric Epilepsy Meets Primary Endpoint

LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial In Pediatric Epilepsy Meets Primary Endpoint

Pfizer Inc. (NYSE: PFE) announced today positive top-line results of a Phase 3 study examining the use of LYRICA ® (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four...

Pfizer Oncology To Showcase Clinical Advances From Its Growing Portfolio And Research Pipeline At ASCO

Pfizer Oncology To Showcase Clinical Advances From Its Growing Portfolio And Research Pipeline At ASCO

Pfizer Inc. today announced that new data from its diversified portfolio of marketed and investigational oncology medicines will be presented at the 54 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5, 2018.

Pfizer's Biosimilar RETACRIT® (epoetin Alfa-epbx) Approved By U.S. FDA

Pfizer's Biosimilar RETACRIT® (epoetin Alfa-epbx) Approved By U.S. FDA

Pfizer Inc. (NYSE:PFE) today announced the United States (U.

3 Cutting-Edge Biotech Stocks That Can Double in Value

3 Cutting-Edge Biotech Stocks That Can Double in Value

These three "strong buy" biotech stocks are primed for outsized growth in the next 12 months. Here's why.

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

President Trump reduced tensions in Korea, raised them in the Middle East, and mainly relieved them for investors in the drug and healthcare industries.

Healthcare Stocks Rebound After President Trump's Speech on Drug Pricing

Healthcare Stocks Rebound After President Trump's Speech on Drug Pricing

President Trump delivered a highly-anticipated speech on lowering the cost of drugs for Americans on Friday afternoon.

Mylan First-Quarter Revenue Misses Estimate Amid Lower Sales of Branded Product

Mylan First-Quarter Revenue Misses Estimate Amid Lower Sales of Branded Product

The EpiPen maker saw a 19% drop in North America net sales due in part to lower sales of branded products.

Pfizer Becomes #3 Most Shorted Dow Stock, Replacing Intel

The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Broker Darlings Of The Dow: Pfizer Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #15 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #235 spot.

TheStreet Quant Rating: B (Buy)